Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.08
+$0.04 · +1.96%
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Previous close
$2.08
+$0.04 · +1.96%
After-hours
$2.08
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Day range
Current $2.08
52-week range
Current $2.08
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
34
Expensive
Sentiment
59
Mixed
Risk
63
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Day range
Current $2.08
52-week range
Current $2.08
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development | 2.41M USD | 13.54M USD | 6.35M USD | 13.49M USD | 6.95M USD |
| Selling, general, and administrative | 8.67M USD | 10.2M USD | 9.02M USD | 11.11M USD | 12.22M USD |
| Operating expenses | 11.08M USD | 23.75M USD | 17.44M USD | 70.54M USD | 19.48M USD |
| Interest income | 685K USD | 711K USD | 911K USD | 246K USD | 77K USD |
| Depreciation and amortization | 7K USD | 7K USD | 11K USD | 124K USD | — |
| Operating income | −11.08M USD | −23.75M USD | −17.44M USD | −70.54M USD | −19.48M USD |
| Net income | −7.79M USD | −13.63M USD | −17.44M USD | −57.39M USD | −12.27M USD |
Company facts updated Oct 10, 2026.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 10, 2023 | 1:6 | — | — |
Stock split | Aug 31, 2021 | 1:8 | — | — |
Stock split | Oct 15, 2015 | 1:10 | — | — |
Effective Jul 10, 2023
1:6
Effective Aug 31, 2021
1:8
Effective Oct 15, 2015
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
